LSD1 Activators
Lysine-specific demethylase 1 (LSD1) activators represent a class of chemical compounds that have garnered significant attention in the field of epigenetics and molecular biology. LSD1, also known as KDM1A, is an enzyme crucial for regulating gene expression by demethylating lysine residues on histone proteins, which are involved in the packaging of DNA within the cell nucleus. These activators are specifically designed to enhance the catalytic activity of LSD1, thereby modulating its function in the epigenetic control of gene transcription.
LSD1 activators typically act by binding to specific sites on the enzyme, promoting its affinity for histone substrates, and increasing its demethylase activity. By doing so, they influence the dynamic modification of histones, leading to changes in chromatin structure and, ultimately, gene expression patterns. This class of compounds has sparked interest due to its potential impact on understanding the epigenetic regulation of various biological processes, including cell differentiation, proliferation, and development. Researchers are actively exploring the molecular mechanisms underlying LSD1 activation and its downstream effects on gene expression, with the hope of shedding light on fundamental biological processes and potential applications in the future.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tranylcypromine | 13492-01-8 | sc-200572 sc-200572A | 1 g 5 g | $175.00 $599.00 | 5 | |
Tranylcypromine is a well-known LSD1 activator and a monoamine oxidase inhibitor. It increases LSD1 activity by binding to its active site and promoting the removal of methyl groups from histone proteins. | ||||||
N-Methyl-N-propargylbenzylamine | 555-57-7 | sc-236062 | 5 g | $68.00 | ||
Similar to tranylcypromine, pargyline is another monoamine oxidase inhibitor that has been shown to activate LSD1. | ||||||
RN 1 dihydrochloride | 1781835-13-9 | sc-397054 | 10 mg | $205.00 | ||
RN-1 is a small molecule LSD1 activator that has shown promise in the context of acute myeloid leukemia (AML) therapy. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP-2509 is a specific LSD1 activator that has been explored for its ability to regulate gene expression in cancer cells, particularly in the treatment of neuroblastoma and small-cell lung cancer. | ||||||
Methylstat | 1310877-95-2 | sc-507374 | 10 mg | $480.00 | ||
Methylstat is a potent LSD1 activator that has been explored as a potential therapy for acute myeloid leukemia (AML) and other malignancies. | ||||||